French drugmaker Ipsen’s Cabometyx (cabozantinib) has been recommended by the National Institute for Health and Care Excellence (NICE) for use in England and Wales for previously treated ...

Exelixis’ cancer drug Cabometyx has been approved in a new liver cancer use in the US, providing a second line therapy option for patients previously treated with Bayer’s Nexavar.

The increase was primarily driven by a rise in sales volume and average net selling price. Cabometyx (cabozantinib) generated revenues of $512.8 million, which beat both the Zacks Consensus ...

Five-year results from a trial examining Exelixis’ Cabometyx as a therapy for previously untreated advanced renal cell carcinoma (RCC) sustaining progression-free (PFS) and overall survival (OS ...

The company generates revenue from its key drugs, CABOMETYX, COMETRIQ, and COTELLIC, along with licensing deals, royalties, and research collaborations. Since the early 2000s, Exelixis ...

After more than five years of follow-up, the findings demonstrated that the efficacy benefits of Cabometyx in combination with Opdivo were sustained long-term. A subgroup analysis by the ...

Significant milestones include the anticipated European approval of Cabometyx for neuroendocrine tumors and the filing of Tovorafenib in Europe in H1 2025, along with pivotal trial results for ...

on Facebook and follow Exelixis on LinkedIn. Exelixis, the Exelixis logo and CABOMETYX are registered U.S. trademarks.

on Facebook and follow Exelixis on LinkedIn. Exelixis, the Exelixis logo and CABOMETYX are registered U.S. trademarks.